论文部分内容阅读
目的:探究他克莫司与小剂量激素联用治疗IgA肾病的临床效果。方法:抽取2016年1月至2020年1月临汾市中心医院收治的80例IgA肾病患者为研究对象，根据治疗方案将其分为对照组和观察组，每组40例。对照组患者接受基础治疗和小剂量激素治疗，观察组在此基础上采用联合他克莫司方案治疗，治疗结束后比较两组患者的治疗效果及不良反应发生情况。结果:治疗后，观察组治疗总有效率(95.00%，38/40)高于对照组(80.00%，32/40)，n P0.05)；治疗后，两组24 h尿蛋白及血肌酐水平均低于治疗前，且观察组24 h尿蛋白水平低于对照组(n P0.05)。观察组不良反应发生率(7.50%，3/40)低于对照组(35.00%，14/40)，n P<0.05。n 结论:小剂量激素与他克莫司联合治疗IgA肾病具有较好的治疗效果，且不良反应较少。“,”Objective:To investigate the clinical efficacy of tacrolimus combined with low-dose hormones in the treatment of patients with immunoglobulin A (IgA) nephropathy.Methods:Eighty patients with IgA nephropathy who were admitted to Linfen Central Hospital from January 2016 to January 2020 were included in the study. According to the treatment options, patients were divided into control group and observation group, with 40 cases in each group. The control group received basic therapy and low-dose hormone therapy. And the observation group was treated with tacrolimus based on the treatment of control group. After treatment, the treatment effective rate and incidence of adverse reactions of the two groups were compared.Results:After treatment, the total effective rate of the observation group (95.00%, 38/40) was higher than that of the control group (80.00%, 32/40), and the difference was statistically significant (n P0.05). After treatment, the levels of 24 h urinary protein and serum creatinine in the two groups were lower than those before treatment, and the 24 h urinary protein level in the observation group was lower than that in the control group (n P0.05). The incidence of adverse reactions in the observation group (7.50%, 3/40) was lower than that in the control group (35.00%, 14/40),n P<0.05.n Conclusions:Low-dose hormone combined with tacrolimus in the treatment of IgA nephropathy has good therapeutic effects and less adverse reactions.